Literature DB >> 18083918

Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin-proteasome system and on to human diseases and drug targeting: Nobel Lecture, December 8, 2004.

Aaron Ciechanover1.   

Abstract

Between the 1950s and 1980s, scientists were focusing mostly on how the genetic code is transcribed to RNA and translated to proteins, but how proteins are degraded has remained a neglected research area. With the discovery of the lysosome by Christian de Duve, it was assumed that cellular proteins are degraded within this organelle. Yet, several independent lines of experimental evidence strongly suggested that intracellular proteolysis is largely nonlysosomal, but the mechanisms involved had remained obscure. The discovery of the ubiquitin-proteasome system resolved this enigma. We now recognize that ubiquitin- and proteasome-mediated degradation of intracellular proteins is involved in the regulation of a broad array of cellular processes, such as cell cycle and division, regulation of transcription factors, and assurance of the cellular quality control. Not surprisingly, aberrations in the system have been implicated in the pathogenesis of many human diseases, malignancies, and neurodegenerative disorders among them, which led subsequently to an increasing effort to develop mechanism-based drugs; one is already in use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083918     DOI: 10.1196/annals.1402.078

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

Review 1.  Global signatures of protein and mRNA expression levels.

Authors:  Raquel de Sousa Abreu; Luiz O Penalva; Edward M Marcotte; Christine Vogel
Journal:  Mol Biosyst       Date:  2009-10-01

2.  Expression of p97/VCP and ubiquitin during postnatal development of the degenerating rat retina.

Authors:  Huseyin Ortak; Sevil Cayli; Ufuk Tas; Seda Ocakli; Erkan Söğüt; Helin Deniz Demir
Journal:  J Mol Histol       Date:  2011-11-19       Impact factor: 2.611

3.  Characterization of cell cycle specific protein interaction networks of the yeast 26S proteasome complex by the QTAX strategy.

Authors:  Robyn M Kaake; Tijana Milenković; Natasa Przulj; Peter Kaiser; Lan Huang
Journal:  J Proteome Res       Date:  2010-04-05       Impact factor: 4.466

Review 4.  Ubiquitin-proteasome pathway and cellular responses to oxidative stress.

Authors:  Fu Shang; Allen Taylor
Journal:  Free Radic Biol Med       Date:  2011-04-08       Impact factor: 7.376

5.  Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

Authors:  William J Irvin; Robert Z Orlowski; Wing-Keung Chiu; Lisa A Carey; Frances A Collichio; Philip S Bernard; Inge J Stijleman; Charles Perou; Anastasia Ivanova; E Claire Dees
Journal:  Clin Breast Cancer       Date:  2010-12-01       Impact factor: 3.225

6.  Proteasome Inhibition After Burn Injury.

Authors:  P Geoff Vana; Heather M LaPorte; Yee M Wong; Richard H Kennedy; Richard L Gamelli; Matthias Majetschak
Journal:  J Burn Care Res       Date:  2016 Jul-Aug       Impact factor: 1.845

Review 7.  Role of ubiquitination in Na,K-ATPase regulation during lung injury.

Authors:  Iiro T Helenius; Laura A Dada; Jacob I Sznajder
Journal:  Proc Am Thorac Soc       Date:  2010-02

Review 8.  Proteasome inhibitors in the treatment of multiple myeloma.

Authors:  J J Shah; R Z Orlowski
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528

9.  A nuclear ubiquitin-proteasome pathway targets the inner nuclear membrane protein Asi2 for degradation.

Authors:  Mirta Boban; Marina Pantazopoulou; Anna Schick; Per O Ljungdahl; Roland Foisner
Journal:  J Cell Sci       Date:  2014-06-13       Impact factor: 5.285

Review 10.  Redox control of protein degradation.

Authors:  Marta Pajares; Natalia Jiménez-Moreno; Irundika H K Dias; Bilge Debelec; Milica Vucetic; Kari E Fladmark; Huveyda Basaga; Samo Ribaric; Irina Milisav; Antonio Cuadrado
Journal:  Redox Biol       Date:  2015-09-09       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.